Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

NYU Langone Medical Center, New York

Icahn School of Medicine at Mount Sinai, New York

Columbia University Medical Center, New York

Northeast Clinical Research Center, Bethlehem

The Children's Hospital of Philadelphia, Philadelphia

Temple University School of Medicine, Philadelphia

University of Pennsylvania, Perelman School of Medicine, Philadelphia

IRCCS Istituti Clinici Maugeri, Pavia

UNC Kidney Center, Pediatrics, Chapel Hill

University North Carolina (UNC) Kidney Center, Chapel Hill

University of Miami Miller School of Medicine, Miami

Miami Children's Hospital, Miami

Vanderbilt University Medical Center, Nashville

The Cleveland Clinic Foundation, Cleveland

Akron Nephrology Associates, Akron

Azienda Ospedaliero Universitaria Careggi, Florence

University of Iowa Children's Hospital, Iowa City

Marshfield Clinic Research Foundation, Marshfield

University of Minnesota, Minneapolis

The Children's Mercy Hospital, Kansas City

Azienda Ospedaliero Universitaria Policlinico di Bari, Bari

Unversity of Oklahoma Health Sciences Center, Oklahoma City

Clinical Advancement Center, San Antonio

Colorado Kidney Care, Denver

Southern Utah Kidney and Hypertension Center, St. George

Los Angeles Biomedical Research Institute, Torrance

Balboa Nephrology Medical Group, San Diego

University of Washington, Seattle

Catholic Health Initiatives Franciscan, Tacoma

Renal and Transplant Associates of New England, PC, Springfield

SUNY Stony Brook Hospital, Stony Brook

General Teaching Hospital Prague, Prague

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome